Filing Flows › Korsana Biosciences (KRSA) › Q1 2025
Korsana Biosciences (KRSA) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 6, 2025
Korsana Biosciences (KRSA) reported revenue of $81K for the first quarter 2025 (Q1 2025) and -96% from the quarter before.
Korsana Biosciences, Q1 2025: revenue $81K, net loss $1.4M, operating cash flow −$968K. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $81K | -96% | — |
| Operating profit | −$1.5M | -390% | — |
| Net earnings | −$1.4M | -370% | — |
| Operating cash flow | −$968K | -369% | — |
What changed
Revenue was $81K in Q1 2025, down 96% from the previous quarter.
Operating costs exceeded revenue by $1.5M, an operating margin of -1798.8%. The quarter ended with a net loss of $1.4M, after a profit of $530K the previous quarter.
Operating cash flow was −$1.0M. Non-cash charges added back $114K of share-based compensation. Working capital and other items added $347K.
Questions
What was Korsana Biosciences' revenue in the first quarter 2025?
Korsana Biosciences (KRSA) reported revenue of $81K for the first quarter 2025 (Q1 2025) and -96% from the quarter before.